# TD-0903 for ALI Associated With COVID-19

> **NCT04402866** · PHASE2 · COMPLETED · sponsor: **Theravance Biopharma** · enrollment: 235 (actual)

## Conditions studied

- Acute Lung Injury (ALI) Associated With COVID-19
- Lung Inflammation Associated With COVID-19

## Interventions

- **DRUG:** TD-0903
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04402866
- **Lead sponsor:** Theravance Biopharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-24
- **Primary completion:** 2021-04-21
- **Final completion:** 2021-04-21
- **Target enrollment:** 235 (ACTUAL)
- **Last updated:** 2022-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04402866

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04402866, "TD-0903 for ALI Associated With COVID-19". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04402866. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*